1cP-LSD Stats & Data

1cP-LSD was developed by Lizard Labs, a research chemical laboratory based in the Netherlands, as a legal alternative to LSD. The compound emerged on the grey market around 2019, reportedly created in anticipation of the impending prohibition of 1P-LSD in Germany. Like its predecessor, 1cP-LSD is widely regarded as a prodrug of LSD, converting to the parent compound following administration. The substance belongs to a broader wave of designer lysergamide analogs that have appeared on the research chemical market since the mid-2010s, including AL-LAD, ETH-LAD, and ALD-52. This pattern of novel analog development has been characteristic of the lysergamide research chemical scene, with each new prohibition prompting the emergence of structurally related alternatives. When Germany banned 1cP-LSD in July 2021, 1V-LSD promptly appeared on the market as its replacement, continuing this cycle of regulatory cat-and-mouse. Beyond its presence in the recreational research chemical market, 1cP-LSD has attracted some preliminary scientific attention. The compound has been investigated in veterinary contexts as a potential treatment for anxiety in dogs, representing an unusual application within psychedelic research.

The toxicity and long-term health effects of recreational 1cP-LSD use have not been studied. This is because 1cP-LSD is a research chemical with almost no history of human use. However, as with LSD and psychedelics in general, it is likely that 1cP-LSD can act as a trigger for those with underlying mental disorders. Those with a personal or family history of mental illness are generally advised not to use this substance, particularly when outside of a supervised medical setting. It is strongly recommended that one uses harm reduction practices when using this substance.

Effects aggregated from 5 experience reports (5 single-substance Erowid)

Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.

Too few reports for bars: these effects come from 5 single-substance Erowid reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

Also reported in combinations. In the 6 1cP-LSD reports where another drug was taken too, 1 mentions hospital, emergency services or an overdose, 0 a seizure and 0 psychosis (too few reports for percentages). In the 5 single-substance reports: 0, 0 and 0. These are not in the figures above: they cannot be put down to 1cP-LSD alone, and a mention is not always something that happened to the writer.

From 26 of 26 recorded dose entries: those that state a weight (mg, g or µg), in routes with at least five of them. Values above Q3 + 3×IQR, far above what people typically take, are left out; they can include real heavy doses and overdoses, not only mistakes.

Most co-occurring substances, as a share of all 11 reports filed under 1cP-LSD

Too few reports for bars: these combinations come from 11 reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

• THC 4 of 11

Most common forms and preparations, as a share of the 10 reports that give one

Too few reports for bars: these forms come from 10 reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

• Blotter / Tab 10 of 10

Redosing behavior across 10 reports